FDA Clears Biotech Drug Copycats, But Buying Them Isn't So Easy 2 hours ago
In 2016, Roche Holding AG sold $3 billion worth of its blockbuster biotechnology drug Avastin. Last week, the U.S. Food and Drug Administration approved what's expected to be a less-expensive version.
from Biotech News
0 Comments